We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Daniel J. Roberts
Daniel J. Roberts
Products
PRODUCTS
Semler Research Center Private Ltd.
Charles R. Bonapace
,
Arindam Dasgupta
,
Daniel J. Roberts
, and
Dipesh Shah
Price:
$117.00
View
NATCO Pharma, Ltd.
Daniel J. Roberts
Price:
$117.00
View
Aurobindo Pharma, Ltd.
Parul M. Patel
and
Daniel J. Roberts
Price:
$117.00
View
Alehem International Pvt. Ltd.
Kellia N. Hicks
and
Daniel J. Roberts
Price:
$117.00
View
Amoli Organics Pvt. Ltd.
Daniel J. Roberts
Price:
$117.00
View
Hospira Healthcare India Pvt.
Thomas J. Arista
and
Daniel J. Roberts
Price:
$117.00
View
Parabolic Drugs Ltd.
Daniel J. Roberts
Price:
$117.00
View
Glenmark Pharmaceuticals, Ltd.
Daniel J. Roberts
Price:
$117.00
View
Hetero
Daniel J. Roberts
Price:
$117.00
View
Glenmark Pharmaceuticals, Ltd.
Daniel J. Roberts
Price:
$117.00
View
View All Products by Daniel J. Roberts
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
